SUMMARY. The quality of near-patient blood glucose measurement was audited in our hospitals in 1990, when a diversity of glucose meters were in use, by sending three samples of unknown (to the meter user) concentration to each user and collecting and analysing the results produced. The overall performance was unsatisfactory with a mean coefficient of variation (CY) of 23·5%. A scheme involving training, quality control and external quality assurance was introduced in 1993 based on the Bayer Glucometer II meter. This meter was used exclusively throughout our hospitals. Data from the quality assurance scheme showed that the overall CY fell initially to 14-16% and then settled at about 10-12% for the following 2 years. Unacceptable results (those more than two standard deviations from the mean) were 8-12% of the total. A new meter was introduced in 1995 (the Bayer Glucometer 4) which had the advantages of 'no-wipe' and automatic timing technology and in the subsequent year overall CY fell to 5--6% and has remained at this level. The frequency of unacceptable results fell to 5-7%. The improved precision figures encouraged us to change criteria for acceptability to mean ± 15%. Using these criteria the level of unacceptable results is now 1-2%. This study shows that introducing training, quality control procedures, a quality assurance scheme and improved meter technology all backed by laboratory expertise can produce significant improvement in the quality of near patient blood glucose measurement.
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In the West Glasgow Hospitals University NHS Trust there are approximately three times as many blood glucose measurements carried out outside the laboratory as there are by conventionallaboratory analysis (based on the number of test strips issued to the wards). It is therefore important to attempt to ensure that the results produced at the bedside are of sufficiently good quality to guide therapy.
The death of a patient on whom near-patient blood glucose monitoring was considered to have been faulty lead to the issue of a UK Hazard Warning Notice in 1987.
1 This document stated:
The use of blood meters by untrained staff, without adequate management supervision of the equipment and without the use of quality control procedures, can lead to misleading results adversely affecting the treatment of patients.
Correspondent: Mr A G Rumley.
The warning highlighted the need for equipment selection, training, quality control and quality assurance procedures to be introduced for near patient testing of blood glucose, and more detailed guidelines have been published by a working party of the UK Association of Clinical Biochernists.i A number of publications have documented the poor quality of near-patient measurement of blood glucose and recommended quality assurance procedures for monitoring and improving the quality of results produced.l-' There are also a number of published quality assurance schemes.s!' but little has been published on the effect of a programme of meter rationalization, training, quality control and quality assurance combined with improved meter technology on the quality of near patient glucose measurement over an extended period.
This study demonstrates stepwise improvements in near-patient blood glucose measure-ment following the introduction of such a programme.
METHODS
Before any scheme was introduced in our hospitals five main types of meter were in use: Ames Glucometer I, and Ames Glucometer II (Bayer Diagnostics, Newbury, UK), BCL Refiolux II and BCL Refiocheck (Boehringer Mannheim UK, Lewes, UK) and Hypoguard Hypocount (Hypoguard Ltd, Woodbridge, UK). Each of these meters had a different test strip, method of calibration, and mode of use, with scope therefore for confusion when users changed from one test system to another and the possibility of erroneous results.
The quality of analysis on these meters was assessed by sending three samples (Sugar Chex, Streck Laboratories Inc, Omaha, NE, USA) with unknown (to the user) glucose concentration to each meter user for analysis. This material was also analysed 20 times over a I week period in the laboratory by our routine glucose method (glucose oxidase on a Cobas Bio analyser; Roche Diagnostics, Welwyn Garden City, UK) and also on a single blood glucose meter (Ames Glucometer II) in the laboratory. Subsequently each meter site was visited and the analysis was repeated by qualified laboratory staff using the same material on each of the ward based meters.
The results of this survey were unacceptable and it was therefore decided that a radical change to existing practice was required. Following discussions with various meter manufacturers a system based on the Ames Glueometer II was introduced in January 1993.
All existing meters were removed from the wards and replaced with only one meter type, the Ames Glucometer II. Simultaneously a training scheme, ward quality control procedures and a quality assurance scheme organized and run by the clinical biochemistry department were introduced. Each ward was provided with a quality control (Qq log book and a set of guidelines on the measurement of blood glucose which included advice on what to do in case of problems and specified a contact in the laboratory. In January 1995 the Glucometer II was replaced throughout the wards of the West Glasgow University NHS Trust with a new meter, the Bayer Glucometer 4. The precision of the Glucometer 4 was established in the laboratory by carrying out the replicate analysis Ann C/in Biochem 1997: 34 of both control solutions and whole blood over the analytical range of the meter.
Training of all nurses authorized to carry out blood glucose measurement (qualified nurses only) was carried out by Bayer Diagnostics Nurse Educators. Initially this was carried out by holding daily training sessions over 2 weeks when the meters were first introduced, then at less frequent intervals. All new staff are trained during their induction period. A record of this training is kept in the nurse's personal file. The training covers the following areas:
Sample collection and disposal, including health and safety aspects 2 Basic principles of the analysis 3 Use of the meter including calibration, quality control, cleaning and troubleshooting 4 Documentation of results 5 Consequences of improper use 6 The importance of participation In the quality assurance scheme.
Each ward was provided with a bottle of Bayer Glucotide control solution and instructed to carry out a control measurement before each patient test or batch of patient tests and to record the control measurements in the record book provided, together with the signature of the analyst. This helps with trouble-shooting and ensures that proper procedures have been followed.
Quality assurance (QA) was provided by the laboratory sending out a sample of Bayer Diagnostics Proficiency solution with unknown concentration (concentration modified by the laboratory, ranging from 2·6 to 17·5 mmol(L, with no replication of samples) to each meter user at approximately 6 week intervals for analysis as if they were finger prick samples. When results were returned to the laboratory they were analysed by computer (using software supplied by the Biochemistry Department, Crosshouse Hospital, Kilmarnock, UK and modified in our laboratory) and a report was sent to the user giving them a performance rating: Good, Acceptable or Unacceptable according to whether the result was within I, within 2 or outside 2 standard deviations from the mean, respectively.
All Glucometer II and Glucometer 4 meters, QC solutions and log books and proficiency solutions were supplied by Bayer Diagnostics. In addition all the training of nurses, follow up of poor performance and retraining was carried out by Bayer Diagnostics personnel.
RESULTS
The results of the initial audit of glucose meter performance on five different types of meter showed considerable variation in the quality of results (Table I ). The mean coefficient of variation (CV) for laboratory measurement of glucose (Cobas Bio) was 2·2% and using a glucose meter (Glucometer II) in the laboratory was 3·5%. Both are acceptable levels of precision. However measurement on ward glucose meters gave an overall mean CV of 25% with a value of 34% for a sample with low glucose concentration. An attempt to determine whether this was due to meter variability or to differences between operators by repeating the analysis using the same operator that carried out the laboratory glucose meter measurements demonstrated that the poor performance was partially due to imprecision inherent in using different meters and partially due to imprecision due to different (non-laboratory trained) operators. The number of meters in this survey was 23. A further six were unable to return results because of non-functioning meters (4), inability to calibrate the meter (I) or no reason given (I).
Following the introduction of the training and QA scheme the overall meter precision was monitored at approximately 6 week intervals for a period of 2 years using the Glucometer II. A new meter (Glucometer 4) was then introduced, staff were retrained and precision data was collected for a further year. The results are shown in Fig. I and demonstrate a progressive improvement with an initial fall of the CV to 14-16% which fell further when the scheme was established to 10-12% and stayed at this level until the new meter was introduced. It then fell again to 5-6% and has remained at about this level ever since. The difference in precision after introducing the new meter was highly significant (P<O·OOOI) using Student's t test. The number of meters in the QA scheme in our hospitals is approximately 100.
A report is sent to each participant giving a performance rating for each meter. Performance is 'good' when the result falls within one standard deviation (SD) of the mean, 'acceptable' if the result is within two SDs and 'unacceptable' when outside 2 SD from the mean. Using these criteria between 8% and 12% of participants produced 'unacceptable' results using the Glucometer II and this figure remained fairly static for the 2 year period of the scheme. When the Glucometer 4 was introduced the frequency of unacceptable results fell to 5-7%. However because of the improved precision of the overall results we decided that the criteria for acceptability should be changed because we were judging results as 'unacceptable' that would be acceptable in a clinical setting. The new criteria were based on the consensus statement produced by the American Diabetes Association and other organizations'? which recommends that Self Monitoring of Blood Glucose (SMBG) measurements should be within 15% of the reference measurement. In our scheme the overall trimmed mean is used as the reference value and results more than 15% from this value are deemed 'unacceptable'. Results less than 7·5% from the mean are judged to be 'good' and results between 7·5% and 15% from the mean are judged 'acceptable'. Following the change of criteria the frequency of 'unacceptable' results is now at 1-2%.
The coefficients of variation of glucose analysis on the Glucometer 4 in the laboratory using control solutions were 5,6%, 5-4% and the new meters. The stability of the two solutions was good and was not considered to be a contributing factor. The number of data points in the original survey was much smaller than the number in the subsequent EQA scheme. This does not invalidate the conclusions from the statistical analysis of the data but it does mean that the statistics from the larger group will be more reliable.
Identification of poor performers and follow up with retraining had no further discernible effect on the overall CV. It was disappointing that the precision could not be improved further but our failure to improve performance by retraining is similar to the experience of others.':'
The only way that performance could be improved was to introduce new meters which used non-wipe technology and automatic reaction timing, thereby removing the two greatest sources of error in the measurement process. This had the effect of reducing the CV to 5-6% where it has remained ever since. This is a much more acceptable level of precision and compares well with what is achieved in UK-wide EQA schemes for glucose measurement.
We also assessed the quality of results by looking at the number of 'unacceptable' results produced in each quality assurance run. Unacceptable results were defined as those results falling outside 2 SD from the overall mean after the results had been trimmed to exclude gross errors (i.e. results more than 3 SD from the mean). This identifies the gross errors and the worst 5% of the remaining results. At the beginning about 7% of results were unacceptable but this increased to 10-12% (perhaps reflecting some complacency after the initial enthusiasm) and remained there until the new meters were introduced when the proportion fell to 5-6%. At this point we had to change the criteria for acceptability because it became apparent to us that we were assessing results as analytically unacceptable that were obviously within a clinically acceptable range. We therefore decided to adopt a range of 15% either side of the mean value as being acceptable, which conforms to the recommendations in the Consensus Statement on Blood Glucose Self Monitoring of The American Diabetic Association.'! This creates a more generous range for error than our initial criteria and therefore produced a smaller proportion of results deemed to be 'unacceptable' (1-2%).
The only significant difficulty that remained was that the rate of return of results was static at On whole blood the CVs were 6,7%, 4·9% and 7·1% at 5'3, 9·9 and 24·3mmol/L, respectively.
It is clear from the results shown in Fig. 1 that the situation before laboratory intervention was unsatisfactory if not dangerous. The immediate effect of removing obsolete meters and getting rid of the proliferation of different meter types was to remove a major source of potential error, in that there was no scope for the wrong test strip to be used and the likelihood of incorrect operation of the meter was reduced. The introduction of a training scheme and ward quality control procedures combined with meter rationalization had an immediate effect on the overall precision of ward based glucose measurement, bringing the overall CV down from 25% to about 15%. After the programme was established the CV fell further and settled at 10-12%, remaining at about this level until new meter technology became available. Another possible reason for the improved CV was the different proficiency solution used. The initial survey used an artificial whole blood which required mixing before use whilst the External Quality Assurance (EQA) scheme used an aqueous solution which did not. However the initial ward analysis was repeated by laboratory staff (when mixing was carried out properly). The different matrix of the solutions may have had an effect but within-laboratory precision was better using the artificial whole blood in the initial survey than with the control solutions on about 80%, and threats and encouragement did not increase this figure. Visits by the nurse educator to all defaulters have recently increased this figure to 90%. Notification of default to the appropriate nurse manager is a possible further option to improve the situation. We speculated that the defaulters are likely to be the bad performers in the scheme, but examination of the data shows that it is not the same users that default every time, and there is no obvious correlation with default rate and quality of performance.
One problem that we have encountered in the operation of the meter is in the Intensive Care Unit, where blood is obtained by syringe from indwelling catheters. In this situation it is difficult to obtain a small drop of blood and it is obvious from examination of returned meters that blood can get inside the meter and either this or attempts to clean the meter cause a malfunction. It should be possible to overcome this by using a transfer pipette which can deliver a small drop of blood onto the test strip. This has not affected the quality of results but has led to a number of meters having to be replaced.
Regular training and re-training of operators is important and the need for training becomes apparent through constant examination of QA results, which leads to follow-up visits to poor performers. Through this mechanism re-training is focused in those places where it is most needed, but we also offer re-training to any operator who requests it through a series of open training sessions.
The obvious limitation of the QC and EQA schemes now in use is that they do not reproduce the actual analytical technique used in the assay of a finger prick blood sample. A uniform-sized drop of blood is much easier to obtain from a dropper bottle away from the bedside and it has been demonstrated that aqueous solutions give superior precision of analysis than do whole blood samples. Also the use of QC material and EQA proficiency solution from the same supplier is likely to produce idealized performance. Notwithstanding this the data do give an indication of what is happening to the quality of blood glucose assay at ward level since the improvements in the EQA scheme have occurred using the same solutions throughout.
CONCLUSION
From our experience it is apparent that where there is no supervision of near-patient testing by the laboratory the quality of results produced can be very poor. The introduction of a comprehensive training and quality assurance programme combined with improved meter technology can lead to a situation where the quality of near-patient blood glucose results approaches that of conventional blood glucose analysis in the laboratory.
